Implanet
Latest round
- Series D
Last raised
- Jul 2010
Total raised
- $28M
Investors
- 5
About Implanet
Founded in 2007 in France, Implanet SA develops and manufactures advanced spinal surgery solutions. Implanet has completed 7 deals to date and has no subsidiaries or parent companies.Implanet specializes in the development and distribution of innovative spinal implants and related medical devices for spinal surgeries. Their core offerings include posterior fixation systems, intervertebral fusion cages, and synthetic bone substitutes, aimed at addressing conditions such as scoliosis.40.Implanet plans to launch new products aimed at improving spinal surgery outcomes and is targeting expansion into emerging markets in Asia and the Middle East by 2025.20 each in 2013.
Who invested in Implanet
5 investors across 2 rounds
See all investors in Implanet
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Implanet
Who invested in Implanet?
Implanet has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Implanet raised?
Implanet has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Implanet last raise money?
Implanet's most recent round on record is a Series D, in Jul 2010.
What does Implanet do?
Founded in 2007 in France, Implanet SA develops and manufactures advanced spinal surgery solutions.
Where is Implanet headquartered?
Implanet is headquartered in France.
Which VCs invest in companies like Implanet?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back medical devices & equipment companies at Implanet's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series D
Raising like Implanet? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.